return equiti ttm
updat model fourth quarter full year result adjust
estim guidanc commentari report fourth quarter
revenu million full year revenu million
beat estim street estim respect time
pre-announce earli januari term guidanc manag re-affirmed
full year revenu guidanc billion billion year-
over-year mark step full year sale growth line
manag long-term revenu guidanc provid analyst day addit
commentari fourth quarter result guidanc see full quarter note strong
finish sever tailwind support upsid guidanc estim
world-wide sale increas sale estim million
year-over-year compar previou estim million though nt
expect similar extent beat rais year particularli manag
directli see impact price affect result year versu last year see
reason continu momentum given number partnership gain traction
mani partnership continu develop strateg impact
particular cite pharmaci commerci smart pen partnership new algorithm
broader push type opportun
 sale increas sale estim million
year-over-year compar previou estim million increas
 sale larg due strong beat fourth quarter partli off-set price
headwind associ move patient pharmaci channel end
updat estim contempl increas sensor transmitt
receiv volum off-set price headwind sale made pharmaci
channel result price headwind estimatesin line
manag guidanc million price headwind look forward
continu think estim conserv sever point upsid
current project increas user base deceler
despit fact on-going shift pharmaci channel expect
acceler new patient add sensor util rate rel flat year-
over-year actual improv patient switch system hard
shut-off day
make continu glucos monitor provid real-tim blood glucos measur trend
display vari period sound alarm patient blood-glucos level stray outsid predefin
model updat fourth quarter result commentari
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
sale decreas intern sale estim million year-over-
year compar previou estim million previous expect anoth strong year
growth intern market lower estim account difficult comp especi
geographi seen sever period strong growth like germani result current estim
slight decreas new patient add intern market though instal base still grow slight
decreas sensor util patient migrat new platform
conclus stock thought
finish continu momentum across entir busi benefit increas market awar
benefit cgm usag expand market access intern geographi head view multipl
posit tailwind deliv upsid current expect includ success move pharmaci intern
invest on-going launch believ well posit marketplac drive adopt cgm
maintain industry-lead posit end long-term potenti market remain larg believ
biggest determin stock next sever year share trade time revenu target
million rate stock outperform
summari chang model
also introduc sale estim million year-over-year ep
estim
newpreviouschangenewpreviouschang sensor growth growth growth milliony/i growth margin oper om net margin quarter guidancefull-year summari chang model import disclosur
